Crinetics Pharmaceuticals, Inc. announced on December 16, 2024, the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations.
Her responsibilities include preparing for the potential launch of paltusotine, the company's lead candidate for acromegaly, and overseeing pre-commercialization activities for its broader pipeline. Ms. Kalofonos brings over 20 years of global pharmaceutical and biotech industry experience, including a track record of leading successful product launches.
This appointment is a pivotal step as Crinetics transitions towards becoming a commercial-stage company. Her expertise in building global commercial organizations and driving breakthrough therapies to market is crucial for the anticipated success of paltusotine and future pipeline candidates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.